Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC - Data support continued development of ADP-A2M4CD8 - - On track to start Pha

Two Confirmed Responses and Five out

of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

- Data support continued development of

- On track to start Phase 2 trial in gastroesophageal

cancers in the first half of 2021 -

PHILADELPHIA, Pa. and OXFORDSHIRE, UK., November

09, 2020 - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the

dose escalation cohorts of its Phase 1 SURPASS trial using ADP-A2M4CD8 in a poster at the Society for the Immunotherapy of Cancer

("SITC") Conference.

In these cohorts of heavily pre-treated patients

with advanced cancers (n=6), three were treated with target doses of 1 billion SPEAR T-cells, and three with target doses

of 5 billion. Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy

or cancer immunotherapy.

"We have seen responses in two out of

six patients treated in the safety cohorts of the SURPASS trial as well as antitumor activity in five of them. The responses and

antitumor activity we have seen with our next-generation ADP-A2M4CD8 SPEAR T-cells, across a range of solid tumors, support our

belief that this is a highly active product," said Ad Rawcliffe, Adaptimmune's Chief Executive Officer. "Based

on these data, we will initiate the Phase 2 trial in gastroesophageal cancers in the first half of 2021 and look forward to identifying

additional indications to take into late-stage development."

There were two confirmed partial responses

(PRs): one in a patient with esophagogastric junction (EGJ) cancer, previously reported, and one in a patient with head and neck

cancer, reported as unconfirmed in May. The four other patients had best overall responses of stable disease (SD). Overall, five

out of six patients treated had initial tumor shrinkage.

In vitro translational data using the

manufactured products from patients in the SURPASS trial indicate that co-expression of the CD8 co-receptor on CD4+

ADP-A2M4 SPEAR T-cells enables them to kill MAGE-A4 expressing target cells with equal potency as CD8+ SPEAR T-cells

targeting MAGE-A4. These data, combined with the responses and antitumor activity observed at low doses, indicate that ADP A2M4D8

may be a more potent product than the first-generation ADP A2M4 SPEAR T-cells.

Best Overall Response (BOR) and maximum changes

from baseline in target lesions in Cohorts 1 and 2

As of data cut-off: October 1, 2020

At SITC, Adaptimmune also presented a poster entitled "Inhibition

of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced

functional potential in vitro." These preclinical data indicate that AKT inhibition during the manufacture of SPEAR T-cells

results in a more consistent expansion and phenotype of the final product. This process is currently being used for manufacture

of ADP-A2M4CD8 for the SURPASS trial.

The Company also presented two posters summarizing data for

the two completed Phase 1 trials with ADP-A2M10 (a previously terminated program).

Adaptimmune is a clinical-stage biopharmaceutical company focused

on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific

Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple

Forward-Looking Statements

This release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain

risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated

by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities

and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization

processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from

those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our

Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements

contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update

such forward-looking statements to reflect subsequent events or circumstances.

S bastien Desprez - VP, Communications and Investor

Juli P. Miller, Ph.D. - Senior Director, Investor Relations

safety, efficacy, and product attributes from the SURPASS trial with ADP A2M4CD8, a SPEAR

T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8

S. Hong1, Jeffrey Clarke2, Tanner Johanns3, Partow Kebriaei1, John V. Heymach1,

Ahmed Galal2, Samuel D. Saibil4, Adrian Sacher4, Francine E. Brophy5, Gareth Betts6,

Natalie Bath6, Will Spinner6, Alex Tipping6, Jessica Tucci5, Raymond Luke5,

Trupti Trivedi5, Quan Lin5, Jean Marc Navenot5, Paula M. Fracasso5,

Karen Miller6, Elliot Norry5, Mark Dudley5, Marcus O. Butler4

Affiliations (Institution, City, State, Country):

1The University of Texas MD Anderson Cancer Center,

Houston, TX, United States of America, 2Duke Cancer Center, Durham, NC, United States of America, 3Washington

University School of Medicine, St. Louis, MO, United States of America,4Princess Margaret Cancer Centre, Toronto, Ontario,

Canada, 5Adaptimmune, Philadelphia, PA, United States of America, 6Adaptimmune, Abingdon, United Kingdom

ongoing SURPASS trial (NCT04044859) evaluates safety and efficacy of next-generation

ADP-A2M4CD8 SPEAR T-cells co-expressing the CD8 co-receptor with the engineered MAGE-A4c1032 T cell receptor

First-in-human trial in HLA-A*02 positive patients (pts) with advanced cancers expressing MAGE-A4 antigen by immunohistochemistry.

Eligible pts undergo apheresis, T cells are isolated, transduced with a Lentiviral vector containing the MAGE-A4c1032

TCR and CD8 co receptor, and expanded. Expansion, transduction level, cellular composition and function of the manufactured

product (MP) are assessed in vitro. Prior to infusion, pts receive lymphodepletion with fludarabine 30 mg/m2/day

for 4 days and cyclophosphamide 600 mg/m2/day for 3 days.

16 July 2020, 5 pts (1 with MRCLS, 2 with esophagogastric junction [EGJ] cancers,

1 with ovarian cancer, and 1 with head and neck cancer) were treated with ADP-A2M4 CD8 (range ~1 to 5.7 billion transduced

cells). No DLTs or SAEs have been reported. To date, 1 pt with EGJ cancer had a partial response (PR per RECIST) and has had progression-free

survival >6 months. One pt with head and neck cancer also had a PR. All other pts have had best overall response of stable disease.

MP expanded by an average of 15.3 fold during manufacturing

(range 5.9 to 25.6-fold). On average, 43% of T cells in the MP expressed the TCR (range 23 to 63%). The fraction of CD4+

cells in the final MP varied (range 45 to 84%). Co expression of the MAGE-A4 TCR and CD8 in CD4+ T-cells

in the patient MP enabled CD4+ T-cells to kill tumor target cells directly in vitro. MAGE-A4 expression in tumor

biopsies varied (H-score range 55 to 300). Transduced T-cells were detected in peripheral blood of all pts. IFN gamma increased

transiently in the serum of 1 pt who responded.

Conclusions: ADP-A2M4CD8

SPEAR T-cells have shown an acceptable safety profile and pts with EGJ cancer and head and neck cancer have demonstrated evidence

of antitumor activity. Translational data and early clinical results indicate that co-expression of the CD8 co-receptor on

CD4+ SPEAR T-cells may increase the potency of the product by conferring additional killing activity to the helper T-cell

subset. This dose escalation trial is ongoing and updated clinical and translational data will be presented.